Wednesday, September 15, 2021 1:00:28 PM
Ham. thx. Rose / Mass also ) You had mentioned that the coupons were a significant part of AMRN's selling / admin spend . I was wondering what that might be .
AMRN states the coupon is worth up to $150 a month which is close to their WAC ( wholesale acquisition cost ) from memory .
So in some cases is the Co almost giving Vascepa away for free ( via its coupon ) ....simply to make a sale ? .....and what % of their sales are like this .
Yes I get Amazons Prime day etc ...BUT Amazon is not running Prime Day every day for a % of its customers .
How many on this board use the coupon , what would their cost be without the coupon and would they still want Brand V without the coupon ...if they didn't own the stock ?
This relates to the question of AMRN selling a generic V ...asked by Mass and others .
Generics don't have the expense of coupon plan ( correct if necessary ) and in some cases the only way AMRN prevents the patient from switching to GV is to offer the coupon to enable the patient to end up with a lower price.
In effect giving them Brand Vascepa for almost nothing .
So I'm asking... Is there any way to tell what % of AMRN's sales use the coupon and what that costs the Co ?
Rose ...thx for that note re the Label. You are correct . My Crestor bottle clearly states " Take 1 tablet etc to prevent heart attacks and strokes "
Why doesn't the Brand Vascepa bottle say the same ...anyone ?
Kiwi
AMRN states the coupon is worth up to $150 a month which is close to their WAC ( wholesale acquisition cost ) from memory .
So in some cases is the Co almost giving Vascepa away for free ( via its coupon ) ....simply to make a sale ? .....and what % of their sales are like this .
Yes I get Amazons Prime day etc ...BUT Amazon is not running Prime Day every day for a % of its customers .
How many on this board use the coupon , what would their cost be without the coupon and would they still want Brand V without the coupon ...if they didn't own the stock ?
This relates to the question of AMRN selling a generic V ...asked by Mass and others .
Generics don't have the expense of coupon plan ( correct if necessary ) and in some cases the only way AMRN prevents the patient from switching to GV is to offer the coupon to enable the patient to end up with a lower price.
In effect giving them Brand Vascepa for almost nothing .
So I'm asking... Is there any way to tell what % of AMRN's sales use the coupon and what that costs the Co ?
Rose ...thx for that note re the Label. You are correct . My Crestor bottle clearly states " Take 1 tablet etc to prevent heart attacks and strokes "
Why doesn't the Brand Vascepa bottle say the same ...anyone ?
Kiwi
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
